{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:19:17Z","timestamp":1792685957511,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s00277-025-06373-3","type":"journal-article","created":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T07:18:29Z","timestamp":1745479109000},"page":"2605-2616","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Incidence of pneumonia among bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia: a systematic review and meta-analysis of clinical trials"],"prefix":"10.1007","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2083-5510","authenticated-orcid":false,"given":"Himil","family":"Mahadevia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Ponvilawan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuj","family":"Shrestha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,24]]},"reference":[{"issue":"2","key":"6373_CR1","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1124\/jpet.117.242909","volume":"363","author":"T Barf","year":"2017","unstructured":"Barf T, Covey T, Izumi R, van de Kar B, Gulrajani M, van Lith B, van Hoek M, de Zwart E, Mittag D, Demont D, Verkaik S, Krantz F, Pearson PG, Ulrich R, Kaptein A (2017) Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile. J Pharmacol Exp Ther 363(2):240\u2013252. https:\/\/doi.org\/10.1124\/jpet.117.242909","journal-title":"J Pharmacol Exp Ther"},{"issue":"12","key":"6373_CR2","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1002\/eji.1830231210","volume":"23","author":"M de Weers","year":"1993","unstructured":"de Weers M, Verschuren MC, Kraakman ME, Mensink RG, Schuurman RK, van Dongen JJ, Hendriks RW (1993) The Bruton\u2019s tyrosine kinase gene is expressed throughout B cell differentiation, from early precursor B cell stages preceding immunoglobulin gene rearrangement up to mature B cell stages. Eur J Immunol 23(12):3109\u20133114. https:\/\/doi.org\/10.1002\/eji.1830231210","journal-title":"Eur J Immunol"},{"key":"6373_CR3","doi-asserted-by":"publisher","first-page":"686768","DOI":"10.3389\/fimmu.2021.686768","volume":"12","author":"M Palma","year":"2021","unstructured":"Palma M, Mulder TA, \u00d6sterborg A (2021) BTK Inhibitors in Chronic Lymphocytic Leukemia: Biological Activity and Immune Effects. Front Immunol 12:686768. https:\/\/doi.org\/10.3389\/fimmu.2021.686768","journal-title":"Front Immunol"},{"issue":"5","key":"6373_CR4","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1182\/blood-2011-10-386417","volume":"119","author":"S Ponader","year":"2012","unstructured":"Ponader S, Chen SS, Buggy JJ, Balakrishnan K, Gandhi V, Wierda WG, Keating MJ, O\u2019Brien S, Chiorazzi N, Burger JA (2012) The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 119(5):1182\u20131189. https:\/\/doi.org\/10.1182\/blood-2011-10-386417","journal-title":"Blood"},{"issue":"4","key":"6373_CR5","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1509981","volume":"374","author":"JC Byrd","year":"2016","unstructured":"Byrd JC, Harrington B, O\u2019Brien S, Jones JA, Schuh A, Devereux S, Chaves J, Wierda WG, Awan FT, Brown JR, Hillmen P, Stephens DM, Ghia P, Barrientos JC, Pagel JM, Woyach J, Johnson D, Huang J, Wang X, Kaptein A, Lannutti BJ, Covey T, Fardis M, McGreivy J, Hamdy A, Rothbaum W, Izumi R, Diacovo TG, Johnson AJ, Furman RR (2016) Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med 374(4):323\u2013332. https:\/\/doi.org\/10.1056\/NEJMoa1509981","journal-title":"N Engl J Med"},{"issue":"5","key":"6373_CR6","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1182\/blood-2009-03-212837","volume":"114","author":"MP Quiroga","year":"2009","unstructured":"Quiroga MP, Balakrishnan K, Kurtova AV, Sivina M, Keating MJ, Wierda WG, Gandhi V, Burger JA (2009) B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. Blood 114(5):1029\u20131037. https:\/\/doi.org\/10.1182\/blood-2009-03-212837","journal-title":"Blood"},{"key":"6373_CR7","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2147\/blctt.S326627","volume":"12","author":"F St-Pierre","year":"2022","unstructured":"St-Pierre F, Ma S (2022) Use of BTK Inhibitors in Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma (CLL\/SLL): A Practical Guidance. Blood Lymphat Cancer 12:81\u201398. https:\/\/doi.org\/10.2147\/blctt.S326627","journal-title":"Blood Lymphat Cancer"},{"issue":"24","key":"6373_CR8","doi-asserted-by":"publisher","first-page":"3327","DOI":"10.1182\/blood.2020009617","volume":"137","author":"JC Byrd","year":"2021","unstructured":"Byrd JC, Woyach JA, Furman RR, Martin P, O\u2019Brien S, Brown JR, Stephens DM, Barrientos JC, Devereux S, Hillmen P, Pagel JM, Hamdy A, Izumi R, Patel P, Wang MH, Jain N, Wierda WG (2021) Acalabrutinib in treatment-naive chronic lymphocytic leukemia. Blood 137(24):3327\u20133338. https:\/\/doi.org\/10.1182\/blood.2020009617","journal-title":"Blood"},{"issue":"4","key":"6373_CR9","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1056\/NEJMoa2211582","volume":"388","author":"JR Brown","year":"2023","unstructured":"Brown JR, Eichhorst B, Hillmen P, Jurczak W, Ka\u017amierczak M, Lamanna N, O\u2019Brien SM, Tam CS, Qiu L, Zhou K, Simkovic M, Mayer J, Gillespie-Twardy A, Ferrajoli A, Ganly PS, Weinkove R, Grosicki S, Mital A, Robak T, Osterborg A, Yimer HA, Salmi T, Wang MD, Fu L, Li J, Wu K, Cohen A, Shadman M (2023) Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia. N Engl J Med 388(4):319\u2013332. https:\/\/doi.org\/10.1056\/NEJMoa2211582","journal-title":"N Engl J Med"},{"issue":"1","key":"6373_CR10","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2300696","volume":"389","author":"AR Mato","year":"2023","unstructured":"Mato AR, Woyach JA, Brown JR, Ghia P, Patel K, Eyre TA, Munir T, Lech-Maranda E, Lamanna N, Tam CS, Shah NN, Coombs CC, Ujjani CS, Fakhri B, Cheah CY, Patel MR, Alencar AJ, Cohen JB, Gerson JN, Flinn IW, Ma S, Jagadeesh D, Rhodes JM, Hernandez-Ilizaliturri F, Zinzani PL, Seymour JF, Balbas M, Nair B, Abada P, Wang C, Ruppert AS, Wang D, Tsai DE, Wierda WG, Jurczak W (2023) Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia. N Engl J Med 389(1):33\u201344. https:\/\/doi.org\/10.1056\/NEJMoa2300696","journal-title":"N Engl J Med"},{"issue":"1","key":"6373_CR11","first-page":"98","volume":"25","author":"VA Morrison","year":"1998","unstructured":"Morrison VA (1998) The infectious complications of chronic lymphocytic leukemia. Semin Oncol 25(1):98\u2013106","journal-title":"Semin Oncol"},{"issue":"12","key":"6373_CR12","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1182\/bloodadvances.2018028761","volume":"3","author":"SE Coutre","year":"2019","unstructured":"Coutre SE, Byrd JC, Hillmen P, Barrientos JC, Barr PM, Devereux S, Robak T, Kipps TJ, Schuh A, Moreno C, Furman RR, Burger JA, O\u2019Dwyer M, Ghia P, Valentino R, Chang S, Dean JP, James DF, O\u2019Brien SM (2019) Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Blood Adv 3(12):1799\u20131807. https:\/\/doi.org\/10.1182\/bloodadvances.2018028761","journal-title":"Blood Adv"},{"issue":"5","key":"6373_CR13","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.3390\/cancers15051504","volume":"15","author":"AM Frustaci","year":"2023","unstructured":"Frustaci AM, Deodato M, Zamprogna G, Cairoli R, Montillo M, Tedeschi A (2023) Next Generation BTK Inhibitors in CLL: Evolving Challenges and New Opportunities. Cancers (Basel) 15(5):1504. https:\/\/doi.org\/10.3390\/cancers15051504","journal-title":"Cancers (Basel)"},{"issue":"4","key":"6373_CR14","doi-asserted-by":"publisher","first-page":"e140","DOI":"10.3324\/haematol.2014.119669","volume":"100","author":"M Borge","year":"2015","unstructured":"Borge M, Bel\u00e9n Almej\u00fan M, Podaza E, Colado A, Fern\u00e1ndez Grecco H, Cabrejo M, Bezares RF, Giordano M, Gamberale R (2015) Ibrutinib impairs the phagocytosis of rituximab-coated leukemic cells from chronic lymphocytic leukemia patients by human macrophages. Haematologica 100(4):e140-142. https:\/\/doi.org\/10.3324\/haematol.2014.119669","journal-title":"Haematologica"},{"issue":"2","key":"6373_CR15","doi-asserted-by":"publisher","first-page":"478","DOI":"10.3324\/haematol.2019.219220","volume":"105","author":"D Blez","year":"2020","unstructured":"Blez D, Blaize M, Soussain C, Boissonnas A, Meghraoui-Kheddar A, Menezes N, Portalier A, Combadi\u00e8re C, Leblond V, Ghez D, Fekkar A (2020) Ibrutinib induces multiple functional defects in the neutrophil response against Aspergillus fumigatus. Haematologica 105(2):478\u2013489. https:\/\/doi.org\/10.3324\/haematol.2019.219220","journal-title":"Haematologica"},{"issue":"20","key":"6373_CR16","doi-asserted-by":"publisher","first-page":"6139","DOI":"10.3390\/jcm11206139","volume":"11","author":"N Garg","year":"2022","unstructured":"Garg N, Padron EJ, Rammohan KW, Goodman CF (2022) Bruton\u2019s Tyrosine Kinase Inhibitors: The Next Frontier of B-Cell-Targeted Therapies for Cancer, Autoimmune Disorders, and Multiple Sclerosis. J Clin Med 11(20):6139. https:\/\/doi.org\/10.3390\/jcm11206139","journal-title":"J Clin Med"},{"issue":"25","key":"6373_CR17","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","volume":"131","author":"M Hallek","year":"2018","unstructured":"Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, D\u00f6hner H, Hillmen P, Keating M, Montserrat E, Chiorazzi N, Stilgenbauer S, Rai KR, Byrd JC, Eichhorst B, O\u2019Brien S, Robak T, Seymour JF, Kipps TJ (2018) iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood 131(25):2745\u20132760. https:\/\/doi.org\/10.1182\/blood-2017-09-806398","journal-title":"Blood"},{"key":"6373_CR18","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.3389\/fimmu.2020.02158","volume":"11","author":"S Fiorcari","year":"2020","unstructured":"Fiorcari S, Maffei R, Vallerini D, Scarf\u00f2 L, Barozzi P, Maccaferri M, Potenza L, Ghia P, Luppi M, Marasca R (2020) BTK Inhibition Impairs the Innate Response Against Fungal Infection in Patients With Chronic Lymphocytic Leukemia. Front Immunol 11:2158. https:\/\/doi.org\/10.3389\/fimmu.2020.02158","journal-title":"Front Immunol"},{"issue":"1","key":"6373_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17(1):1\u201312. https:\/\/doi.org\/10.1016\/0197-2456(95)00134-4","journal-title":"Control Clin Trials"},{"issue":"3","key":"6373_CR20","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/s41375-019-0602-x","volume":"34","author":"JA Burger","year":"2020","unstructured":"Burger JA, Barr PM, Robak T, Owen C, Ghia P, Tedeschi A, Bairey O, Hillmen P, Coutre SE, Devereux S, Grosicki S, McCarthy H, Simpson D, Offner F, Moreno C, Dai S, Lal I, Dean JP, Kipps TJ (2020) Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL\/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia 34(3):787\u2013798. https:\/\/doi.org\/10.1038\/s41375-019-0602-x","journal-title":"Leukemia"},{"issue":"10","key":"6373_CR21","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1182\/blood-2018-10-879429","volume":"133","author":"JA Burger","year":"2019","unstructured":"Burger JA, Sivina M, Jain N, Kim E, Kadia T, Estrov Z, Nogueras-Gonzalez GM, Huang X, Jorgensen J, Li J, Cheng M, Clow F, Ohanian M, Andreeff M, Mathew T, Thompson P, Kantarjian H, O\u2019Brien S, Wierda WG, Ferrajoli A, Keating MJ (2019) Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood 133(10):1011\u20131019. https:\/\/doi.org\/10.1182\/blood-2018-10-879429","journal-title":"Blood"},{"issue":"3","key":"6373_CR22","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1400376","volume":"371","author":"JC Byrd","year":"2014","unstructured":"Byrd JC, Brown JR, O\u2019Brien S, Barrientos JC, Kay NE, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Devereux S, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Pocock C, Thornton P, Caligaris-Cappio F, Robak T, Delgado J, Schuster SJ, Montillo M, Schuh A, de Vos S, Gill D, Bloor A, Dearden C, Moreno C, Jones JJ, Chu AD, Fardis M, McGreivy J, Clow F, James DF, Hillmen P (2014) Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 371(3):213\u2013223. https:\/\/doi.org\/10.1056\/NEJMoa1400376","journal-title":"N Engl J Med"},{"issue":"31","key":"6373_CR23","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.1200\/jco.21.01210","volume":"39","author":"JC Byrd","year":"2021","unstructured":"Byrd JC, Hillmen P, Ghia P, Kater AP, Chanan-Khan A, Furman RR, O\u2019Brien S, Yenerel MN, Ill\u00e9s A, Kay N, Garcia-Marco JA, Mato A, Pinilla-Ibarz J, Seymour JF, Lepretre S, Stilgenbauer S, Robak T, Rothbaum W, Izumi R, Hamdy A, Patel P, Higgins K, Sohoni S, Jurczak W (2021) Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial. J Clin Oncol 39(31):3441\u20133452. https:\/\/doi.org\/10.1200\/jco.21.01210","journal-title":"J Clin Oncol"},{"issue":"12","key":"6373_CR24","doi-asserted-by":"publisher","first-page":"e801","DOI":"10.1097\/hs9.0000000000000801","volume":"6","author":"P Ghia","year":"2022","unstructured":"Ghia P, Pluta A, Wach M, Lysak D, \u0160imkovi\u010d M, Kriachok I, Ill\u00e9s \u00c1, de la Serna J, Dolan S, Campbell P, Musuraca G, Jacob A, Avery EJ, Lee JH, Usenko G, Wang MH, Yu T, Jurczak W (2022) Acalabrutinib Versus Investigator\u2019s Choice in Relapsed\/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results. Hemasphere 6(12):e801. https:\/\/doi.org\/10.1097\/hs9.0000000000000801","journal-title":"Hemasphere"},{"issue":"4","key":"6373_CR25","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1002\/cam4.1337","volume":"7","author":"X Huang","year":"2018","unstructured":"Huang X, Qiu L, Jin J, Zhou D, Chen X, Hou M, Hu J, Hu Y, Ke X, Li J, Liang Y, Liu T, Lv Y, Ren H, Sun A, Wang J, Zhao C, Salman M, Sun S, Howes A, Wang J, Wu P, Li J (2018) Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, open-label phase 3 study. Cancer Med 7(4):1043\u20131055. https:\/\/doi.org\/10.1002\/cam4.1337","journal-title":"Cancer Med"},{"issue":"6","key":"6373_CR26","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1111\/cas.14886","volume":"112","author":"K Izutsu","year":"2021","unstructured":"Izutsu K, Ando K, Ennishi D, Shibayama H, Suzumiya J, Yamamoto K, Ichikawa S, Kato K, Kumagai K, Patel P, Iizumi S, Hayashi N, Kawasumi H, Murayama K, Nagai H (2021) Safety and antitumor activity of acalabrutinib for relapsed\/refractory B-cell malignancies: A Japanese phase I study. Cancer Sci 112(6):2405\u20132415. https:\/\/doi.org\/10.1111\/cas.14886","journal-title":"Cancer Sci"},{"issue":"2","key":"6373_CR27","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1182\/blood.2021010845","volume":"139","author":"P Langerbeins","year":"2022","unstructured":"Langerbeins P, Zhang C, Robrecht S, Cramer P, F\u00fcrstenau M, Al-Sawaf O, von Tresckow J, Fink AM, Kreuzer KA, Vehling-Kaiser U, Tausch E, M\u00fcller L, Eckart MJ, Schlag R, Freier W, Gaska T, Balser C, Reiser M, Stauch M, Wendtner CM, Fischer K, Stilgenbauer S, Eichhorst B, Hallek M (2022) The CLL12 trial: ibrutinib vs placebo in treatment-na\u00efve, early-stage chronic lymphocytic leukemia. Blood 139(2):177\u2013187. https:\/\/doi.org\/10.1182\/blood.2021010845","journal-title":"Blood"},{"issue":"10","key":"6373_CR28","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1016\/s1470-2045(16)30212-1","volume":"17","author":"S O'Brien","year":"2016","unstructured":"O\u2019Brien S, Jones JA, Coutre SE, Mato AR, Hillmen P, Tam C, \u00d6sterborg A, Siddiqi T, Thirman MJ, Furman RR, Ilhan O, Keating MJ, Call TG, Brown JR, Stevens-Brogan M, Li Y, Clow F, James DF, Chu AD, Hallek M, Stilgenbauer S (2016) Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncol 17(10):1409\u20131418. https:\/\/doi.org\/10.1016\/s1470-2045(16)30212-1","journal-title":"Lancet Oncol"},{"issue":"9","key":"6373_CR29","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.3324\/haematol.2020.272500","volume":"106","author":"KA Rogers","year":"2021","unstructured":"Rogers KA, Thompson PA, Allan JN, Coleman M, Sharman JP, Cheson BD, Jones D, Izumi R, Frigault MM, Quah C, Raman RK, Patel P, Wang MH, Kipps TJ (2021) Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed\/refractory chronic lymphocytic leukemia. Haematologica 106(9):2364\u20132373. https:\/\/doi.org\/10.3324\/haematol.2020.272500","journal-title":"Haematologica"},{"issue":"8","key":"6373_CR30","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/s1470-2045(22)00293-5","volume":"23","author":"CS Tam","year":"2022","unstructured":"Tam CS, Brown JR, Kahl BS, Ghia P, Giannopoulos K, Jurczak W, \u0160imkovi\u010d M, Shadman M, \u00d6sterborg A, Laurenti L, Walker P, Opat S, Chan H, Ciepluch H, Greil R, Tani M, Trn\u011bn\u00fd M, Brander DM, Flinn IW, Grosicki S, Verner E, Tedeschi A, Li J, Tian T, Zhou L, Marimpietri C, Paik JC, Cohen A, Huang J, Robak T, Hillmen P (2022) Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. Lancet Oncol 23(8):1031\u20131043. https:\/\/doi.org\/10.1016\/s1470-2045(22)00293-5","journal-title":"Lancet Oncol"},{"issue":"11","key":"6373_CR31","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1182\/blood.2019001160","volume":"134","author":"CS Tam","year":"2019","unstructured":"Tam CS, Trotman J, Opat S, Burger JA, Cull G, Gottlieb D, Harrup R, Johnston PB, Marlton P, Munoz J, Seymour JF, Simpson D, Tedeschi A, Elstrom R, Yu Y, Tang Z, Han L, Huang J, Novotny W, Wang L, Roberts AW (2019) Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. Blood 134(11):851\u2013859. https:\/\/doi.org\/10.1182\/blood.2019001160","journal-title":"Blood"},{"issue":"26","key":"6373_CR32","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","volume":"379","author":"JA Woyach","year":"2018","unstructured":"Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, Bartlett NL, Brander DM, Barr PM, Rogers KA, Parikh SA, Coutre S, Hurria A, Brown JR, Lozanski G, Blachly JS, Ozer HG, Major-Elechi B, Fruth B, Nattam S, Larson RA, Erba H, Litzow M, Owen C, Kuzma C, Abramson JS, Little RF, Smith SE, Stone RM, Mandrekar SJ, Byrd JC (2018) Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. N Engl J Med 379(26):2517\u20132528. https:\/\/doi.org\/10.1056\/NEJMoa1812836","journal-title":"N Engl J Med"},{"issue":"1","key":"6373_CR33","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13045-020-00884-4","volume":"13","author":"W Xu","year":"2020","unstructured":"Xu W, Yang S, Zhou K, Pan L, Li Z, Zhou J, Gao S, Zhou D, Hu J, Feng R, Huang H, Ji M, Guo H, Huang J, Novotny W, Feng S, Li J (2020) Treatment of relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study. J Hematol Oncol 13(1):48. https:\/\/doi.org\/10.1186\/s13045-020-00884-4","journal-title":"J Hematol Oncol"},{"issue":"10232","key":"6373_CR34","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/s0140-6736(20)30262-2","volume":"395","author":"JP Sharman","year":"2020","unstructured":"Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, Kamdar M, Munir T, Walewska R, Corbett G, Fogliatto LM, Herishanu Y, Banerji V, Coutre S, Follows G, Walker P, Karlsson K, Ghia P, Janssens A, Cymbalista F, Woyach JA, Salles G, Wierda WG, Izumi R, Munugalavadla V, Patel P, Wang MH, Wong S, Byrd JC (2020) Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet 395(10232):1278\u20131291. https:\/\/doi.org\/10.1016\/s0140-6736(20)30262-2","journal-title":"Lancet"},{"key":"6373_CR35","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae115","author":"NI Agudelo Higuita","year":"2024","unstructured":"Agudelo Higuita NI, Chastain DB, Scott B, Sahra S, Vargas Barahona L, Henao Cordero J, Lee ALH, Tuells J, Henao-Mart\u00ednez AF (2024) Risk of Invasive Fungal Infections in Patients with Chronic Lymphocytic Leukemia treated with Bruton Tyrosine Kinase Inhibitors \u2013 A Case-Control Propensity Score Matched Analysis. Open Forum Infect Dis. https:\/\/doi.org\/10.1093\/ofid\/ofae115","journal-title":"Open Forum Infect Dis"},{"key":"6373_CR36","doi-asserted-by":"publisher","first-page":"S264","DOI":"10.1016\/S2152-2650(22)01321-0","volume":"22","author":"S Vassilopoulos","year":"2022","unstructured":"Vassilopoulos S, Tran Q-L, Kalligeros M, Shehadeh F, Mylonakis E (2022) CLL-105 Cumulative Incidence of Grade 3 or Higher Infections in Patients With CLL\/SLL Treated With BTKi-Based Regimens. Clin Lymphoma Myeloma Leuk 22:S264. https:\/\/doi.org\/10.1016\/S2152-2650(22)01321-0","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"13","key":"6373_CR37","doi-asserted-by":"publisher","first-page":"3240","DOI":"10.3390\/cancers13133240","volume":"13","author":"FR Mauro","year":"2021","unstructured":"Mauro FR, Giannarelli D, Visentin A, Reda G, Sportoletti P, Frustaci AM, Chiarenza A, Ciolli S, Vitale C, Laurenti L, De Paoli L, Murru R, Gentile M, Rigolin GM, Levato L, Giordano A, Del Poeta G, Stelitano C, Ielo C, Noto A, Guarente V, Molica S, Coscia M, Tedeschi A, Gaidano G, Cuneo A, Fo\u00e0 R, Martelli M, Girmenia C, Gentile G, Trentin L (2021) Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib. Cancers 13(13):3240","journal-title":"Cancers"},{"issue":"7","key":"6373_CR38","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1182\/bloodadvances.2020001678","volume":"4","author":"CE Ryan","year":"2020","unstructured":"Ryan CE, Cheng MP, Issa NC, Brown JR, Davids MS (2020) Pneumocystis jirovecii pneumonia and institutional prophylaxis practices in CLL patients treated with BTK inhibitors. Blood Adv 4(7):1458\u20131463. https:\/\/doi.org\/10.1182\/bloodadvances.2020001678","journal-title":"Blood Adv"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06373-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06373-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06373-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T06:37:43Z","timestamp":1749105463000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06373-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,24]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["6373"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06373-3","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,24]]},"assertion":[{"value":"14 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}